AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced
Swiss-based biotech QGel is hoping to offer a novel approach to precision medicine by solving several of the current challenges with ‘organoids’, which can be used to test medicines on orga
European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.
